Alzheimer's Treatment Landscape Expands with New Therapies

2026 marks a significant expansion in Alzheimer's treatment options, with multiple anti-amyloid antibody therapies now approved by the FDA including Leqembi (lecanemab) and Kisunla (donanemab). For decades, Alzheimer's had no disease-modifying treatments—patients and families could only manage symptoms while the disease progressed. That has fundamentally changed.

Researchers are also developing blood-based biomarkers that can detect Alzheimer's years before symptoms appear, potentially enabling earlier intervention when treatments may be more effective. This combination of early detection and disease-modifying therapy represents a new era in dementia care.

The emergence of multiple therapeutic options gives doctors and patients choices, allowing treatment selection based on individual factors including disease stage, other health conditions, and side effect profiles.

Key Facts

• Multiple anti-amyloid therapies now FDA-approved
• Leqembi (lecanemab) and Kisunla (donanemab) among approved treatments
• Blood-based biomarkers in development for early detection
• Source: Bright Focus Foundation, UCSF reporting

Why This Matters

Alzheimer's research saw decades of failed drug trials, with the amyloid hypothesis repeatedly questioned as clinical candidates failed. The recent approvals validate that targeting amyloid can provide clinical benefit, though the effect sizes remain modest. This has reignited investment in Alzheimer's research and given hope to millions of families.

The blood-based biomarker development may prove equally significant, enabling detection during pre-symptomatic phases when intervention might be most effective.

What We Don't Know Yet

Approved treatments show modest clinical benefit—patients decline more slowly, but they still decline. Side effects including brain swelling and bleeding require careful monitoring. High costs (treatments priced at $20,000-$30,000 annually) raise access concerns. The biomarkers remain investigational and not widely available. These treatments target amyloid, but Alzheimer's is a complex disease with multiple contributing factors.

Category: Health & Medicine
Published: April 22, 2026